Decitabine combined with all-trans retinoic acid as treatment in a case of primary myelofibrosis transforming into acute myeloid leukaemia

Yan Lin, Rongrong Lin, Guangquan Zhou, Yue Liu, Weimin Dong, Yang Cao, Xiaobao Xie and Weiying Gu

Abstract
Primary myelofibrosis (PMF) is a type of cloned myeloproliferative neoplasm stemming from haematopoietic stem cells, and tends to transform to acute myeloid leukaemia (AML) in approximately 10–20% of cases over a 10-year period. The transformation into AML has a poor prognosis, with a median overall survival of only 2.6 months in patients receiving supportive treatment. To date, treatment of AML transformation remains poor. The case of a 58-year-old female patient with AML transformed from PMF, who was treated with decitabine combined with all-trans retinoic acid, is reported. The patient had complete remission and a 17-month overall survival from initial diagnosis of transformed AML, with tolerated haematologic toxicity during the treatment period.

Keywords
Decitabine, all-trans retinoic acid, primary myelofibrosis, acute myeloid leukaemia

Date received: 28 August 2018; accepted: 28 November 2018

Introduction
Primary myelofibrosis (PMF) is one type of Philadelphia chromosome-negative myeloproliferative neoplasm, stemming from haematopoietic stem cells. Over a 10-year period, 10–20% of PMF cases would
transform into acute myeloid leukaemia (PMF–tAML),\textsuperscript{1} with subsequent rapid disease progression and a median survival time of only 2.6 months in patients receiving supportive treatment.\textsuperscript{2} Despite this poor outcome risk, less than 10% of patients with PMF–tAML are indicated to receive allogeneic haematopoietic stem cell transplantation.\textsuperscript{3} A few therapeutic agents, such as pegylated interferon-\textalpha-2a,\textsuperscript{4} thalidomide,\textsuperscript{5} azacitidine,\textsuperscript{6} and decitabine\textsuperscript{7} have recently shown positive effects in prolonging overall survival in patients with PMF–tAML.

Here, the case of a patient diagnosed with PMF–tAML treated with decitabine plus all-trans retinoic acid (RA), is presented. Treatment was deemed to be effective, with complete remission achieved after the fourth cycle of therapy. Disease-free survival reached approximately 5 months from the end of treatment, and overall survival reached 17 months from initial diagnosis of tAML. The treatment mechanism and side effects associated with decitabine in treating PMF–tAML are discussed, based on a review of relevant literature.

**Case report**

Relevant approval was obtained from the Ethics Committee of The First People’s Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, China, and the patient, or legal proxy, provided written informed consent for publication of the case.

A 58-year-old Chinese female was admitted to the Department of Haematology, The First People’s Hospital of Changzhou, Third Affiliated Hospital of Soochow University, on 11 May 2014, due to significantly increased white blood cell (WBC) count for the previous 7 years and weakness and leg pain for 1 month. The patient had a history of diabetes mellitus and had been regularly receiving metformin for glycaemic control. A routine physical examination in 2007, the patient was found to have abnormally increased WBCs and splenomegaly, and a bone marrow smear revealed active proliferation and an increase in megakaryocytes. The patient then received a splenectomy at a community hospital and the immunohistochemistry showed active proliferation of the red pulp in the spleen. Following the splenectomy, the patient had been periodically re-examined at the community hospital. The WBC level had continued to rise to $50 \times 10^9$ cells/l and examination of the presence of the breakpoint cluster region gene and the cellular abl ($BCR/ABL$) fusion gene was negative. The patient was prescribed hydroxyurea (1.5–6 g per day, according to WBC levels) and the WBC level was stabilised at $10–12 \times 10^9$ cells/l.

From 1 month prior to hospital admission in May 2014, the patient had developed noticeable dizziness, weakness and severe pain in both calves. At the outpatient clinic, routine blood test results showed a WBC count of $10.89 \times 10^9$ cells/l, haemoglobin (Hb) at 86 g/l and platelet count of $55 \times 10^9$ cells/l. Results from a peripheral blood smear revealed 7% primary cells. Attempts to perform bone marrow aspirations from the anterior superior iliac spine, posterior superior iliac spine and sternum were all unsuccessful due to dry tap.

At hospital admission, physical examinations showed a body temperature of 38.8°C and anaemic appearance, but no swollen superficial lymph nodes, sternal tenderness, hepatomegaly or limb oedema were observed. The routine blood test revealed a WBC count of $8.63 \times 10^9$ cells/l, Hb level of 73 g/l and platelet count of $35 \times 10^9$ cells/l. The peripheral blood smear showed 5% primary cells, 1% premyelocytes, and 20% myelocytes. Flow cytometry of peripheral blood, performed using the BD FACSCalibur\textsuperscript{TM} equipment and associated reagents and antibodies (BD Biosciences, San Jose, CA, USA) according
to the manufacturer’s instructions, showed that blood cells were positive for CD13, CD22, CD33 and CD34. Cytogenetic analysis of peripheral blood revealed the following karyotype: 46, XX, t(7;20) (q21;q13)–11, add (14) (q32), +M[12]. Genetic analysis, performed using an Applied Biosystems™ 7500 Real-Time PCR System (ThermoFisher Scientific, Waltham, MA USA) according to the manufacturer’s instructions, showed the blood samples to be BCR/ABL fusion gene-negative, Janus kinase 2 (JAK2)-V617 gene mutation-positive, MPL proto-oncogene, thrombopoietin receptor (MPL) gene mutation-negative, calreticulin (CALR) gene mutation-negative, immunoglobulin heavy chain (IgH)-negative and T cell receptor (TCR) gene rearrangement-negative. Examination of liver function showed as following: albumin, 27 g/l; lactate dehydrogenase (LDH), 674 U/l; and fasting blood glucose, 7.24 mmol/l. An electrocardiogram showed sinus tachycardia and a change to part of the T wave. Chest X-ray showed increased lung markings. An ultrasound scan showed typical manifestations after splenectomy and gallstones. Posterior bone marrow biopsy revealed granulocyte hyperplasia with a majority of primary and immature granulocytes, significantly decreased megakaryocytes and fibrous tissue proliferation (Figure 1a and 1b). The diagnosis was considered to be PMF transforming into leukaemia, and considering all of the above examination results, a firm diagnosis of PMF–tAML was made.

Following hospital admission, the patient was intermittently infused with red blood cells and apheresis platelets. Four cycles of decitabine (15 mg/m²/day, days 1–5) plus all-trans RA (20 mg/m²/day, days 1–28) was administered as remission inductive therapy. Then each cycle of therapy was given every 4 weeks. The therapy was postponed if blood cell recovery was delayed. Each chemotherapy cycle started on 31 May 2014, 25 June 2014, 6 August 2014 and 14 October 2014, respectively. Following the second treatment cycle, an obvious improvement in routine blood test parameters was achieved. After the third treatment cycle, the routine blood test showed that WBC count, Hb level and platelet count were further improved and bone marrow aspirations were successfully obtained from the sternum. The bone marrow smear showed active proliferation of karyocytes with 58 megakaryocytes observed on the whole bone marrow smear slide, increased platelets and 4%
primitive cells (Figure 1c). Re-examination of blood samples for the presence of the JAK2-V617 gene mutation gave a negative result. The routine blood parameter results, including WBC count, Hb level, platelet count and neutrophil cycle, all returned to normal levels after the fourth treatment cycle (Figure 2a and 2b). Thus, complete remission was achieved. The patient then stopped the decitabine plus all-trans RA therapy, after which, routine blood tests were performed every 2 weeks and showed that WBC count, Hb levels and platelets were all within normal ranges for approximately 5 months (data not shown). In April 2015, the patient developed anaemia and thrombocytopenia again, which indicated disease progression. The patient did not continue with targeted therapy and did not receive any further relevant examinations. The patient died in October 2015 following several months of supportive treatment. The curative effect of treatment with decitabine plus all-trans RA was satisfactory, with a disease-free survival duration of approximately 5 months from the

**Figure 2.** Blood parameters of a 58-year-old female patient during treatment with four cycles of decitabine plus all-trans retinoic acid (4 weeks per cycle) for primary myelofibrosis transformed to acute myeloid leukaemia; Cycles started on 31 May 2014, 25 June 2014, 6 August 2014 and 14 October 2014: (a) white blood cell (WBC) count and absolute neutrophil count (ANC), black arrows indicate start of each chemotherapy cycle; (b) haemoglobin (Hb) levels and platelet (PLT) counts, black arrows indicate start of each chemotherapy cycle.
end of treatment with decitabine plus all-trans RA, and an overall survival of 17 months from initial diagnosis of tAML.

Discussion

Acute myeloid leukaemia that has transformed from PMF is associated with a poor clinical outcome: Median overall survival is only 2.6 months in patients receiving supportive treatment, and only 3.9 months in patients receiving an introductive chemotherapy regimen including anthracyclines plus cytosine arabinoside.\(^2\) Median overall survival in patients with PMF is 3–7 years and it takes approximately 10–15 years for PMF to progress to AML.\(^7\) These data suggest that early detection of PMF may facilitate an improved prognosis.

In 2016, the World Health Organisation proposed a diagnosis standard for prefibrotic/early primary myelofibrosis (prePMF), involving change or abnormality in blood cell count, relevant gene mutations, increasing LDH levels, and splenomegaly.\(^8\) Of particular note is the fact that splenomegaly in the early phase of disease is a possible sign of prePMF or PMF, and genetic analyses may help diagnose prePMF.

The JAK2/signal transducer and activator of transcription (STAT) signalling pathway plays an important role in cell proliferation, differentiation, apoptosis and immune regulation,\(^9\) and many cases of PMF are found to bear a mutation in the JAK2 gene.\(^10\) Protein-tyrosine phosphatase SHP-1 (encoded by the protein tyrosine phosphatase, non-receptor type 6 gene) negatively regulates the JAK2/STAT signalling pathway, and has been shown to be epigenetically inactivated by aberrant hypermethylation of its promoter, which is thought to contribute to the constitutive activation of JAK2/STAT signalling in patients with myeloproliferative neoplasms. Thus, demethylation therapy that targets SHP1 (which is involved in regulating the JAK2/STAT signalling pathway) may contribute to treatment for patients with myeloproliferative neoplasm.\(^11\)

Investigation of methylation using genome arrays has revealed that gene hypermethylation is a promotive factor for PMF transforming to AML.\(^12,13\) Thepot et al.\(^6\) found that the overall response rate (ORR) in patients with myeloproliferative neoplasm transformed to AML, who were treated with azacitidine, was 38%, with a median overall survival of 8 months. Another study reported an ORR of 29% in patients with myeloproliferative neoplasm transformed to AML treated with decitabine, and a median overall survival of 10.5 months.\(^7\) In patients with high-risk PMF treated with decitabine, the ORR was 82% and the median overall survival was 32 months.\(^7\) These data suggest that demethylation drugs, including decitabine, appear to be superior to a regimen of anthracyclines plus cytosine arabinoside in prolonging the overall survival of patients with PMF–tAML.

All-trans RA is a drug that targets acute promyelocytic leukaemia (APL). It not only targets the retinoic acid receptor (RAR)\(^\alpha\) gene to induce differentiation of APL cells, but also targets the RAR\(^\beta\) gene to inhibit tumour cell proliferation and promote tumour cell apoptosis.\(^14\) Numerous researchers have highlighted the synergistic effect of promoting tumour cell apoptosis and differentiation by combination therapy using all-trans RA and decitabine.\(^15–18\) Previous studies found that all-trans RA plus decitabine could induce the apoptosis and differentiation of leukemia cell lines K562, SHI-1 and U937 via upregulation of RAR\(^\beta\) gene expression.\(^15,17,18\) In clinical practice, the ORR to treatment with all-trans RA plus decitabine in patients with myeloid leukaemia who cannot tolerate strong chemotherapy is 58.1%, with a median overall survival of 11 months.\(^19\)

In the present case, the diagnosis of PMF transforming into AML in addition to
complex karyotypes, predicted a poor prognosis. Induction chemotherapy based on cytosine arabinoside has not been found to significantly prolong overall survival and may cause post-chemotherapy bone marrow depression due to toxicity of chemotherapeutic drugs. Thus, in the present case, decitabine plus all-trans RA was administered. After the fourth treatment cycle, complete remission was confirmed. Disease-free survival reached approximately 5 months from the end of treatment with decitabine plus all-trans RA, and the patient had a 17-month overall survival from initial diagnosis of tAML.

Decitabine for treating AML is administered in either 3-day or 5-day regimens. According to the prescribing information for decitabine, there are two recommended regimens for decitabine administration: option 1, decitabine is administered at a dose of 15 mg/m² by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days. The cycle is repeated every 6 weeks; or option 2, decitabine is administered at a dose of 20 mg/m² by continuous intravenous infusion over 1 hour repeated daily for 5 days. The cycle is repeated every 4 weeks. The 3-day regimen (45 mg/m²/day decitabine, 3 times per day for 3 days, 6 weeks for 1 cycle) has been less used due to its severe side effects. In the 5-day regimen, decitabine is administered at 15 mg/m²/day, once a day for 5 days, 4 weeks for 1 cycle. Decitabine dosed at 15 mg/m² has been reported to increase the platelet count by promoting the release of platelets and the maturation of megakaryocytes. Given that the platelet count of the present patient was low, the 5-day regimen of 15 mg/m²/day decitabine, once a day for 5 days, 4 weeks for 1 cycle, was chosen for treatment.

Chen et al. observed that 20 mg/m²/day all-trans RA was superior to 45 mg/m²/day with a similar response rate and reduced side effects in treating AML. Previously, the present authors administered 15 mg/m²/day decitabine (days 1–5) combined with 20 mg/m²/day all-trans RA (days 1–28) to successfully treat 31 cases of myeloid neoplasms not suitable for intensive chemotherapy, with an ORR of 58.1% and a 2-year survival rate of 26.6%. The side effects were mainly tolerable haematologic toxicities. In the present case, the same regimen was used to treat a patient diagnosed with PMF–tAML. The side effects were manageable, avoiding the severe myelosuppression associated with chemotherapy based on cytosine arabinoside administration.

In summary, the case of a patient with PMF–tAML who was successfully treated with a regimen of 15 mg/m²/day decitabine (once daily for 5 days; 4 weeks for 1 cycle) plus all-trans RA, is reported. The case provides evidence and indications that a regimen of decitabine plus all-trans RA may be a safe and effective treatment alternative for PMF–tAML. This regimen may effectively prolong overall survival with minimal side effects and avoid severe myelosuppression following chemotherapy.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
The authors acknowledge the funding contribution of the Natural Science Foundation of Jiangsu Province for Young Scholars (BK 20150253).

References
1. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. *Leukemia* 2013; 27: 1874–1881.
2. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. *Blood* 2005; 105: 973–977.
3. Tallarico M and Odenike O. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies. *Curr Hematol Malig Rep* 2015; 10: 112–117.

4. Berneman ZN, Anguille S, Van Marck V, et al. Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis. *Br J Haematol* 2010; 149: 152–155.

5. Huang WH, Li MS, Chu SC, et al. Thalidomide treatment in a myelofibrosis patient with leukemia transformation. *Int J Hematol* 2014; 99: 188–192.

6. Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). *Blood* 2010; 116: 3735–3742.

7. Badar T, Kantarjian HM, Ravandi F, et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. *Leuk Res* 2015; 39: 950–956.

8. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016; 127: 2391–2405.

9. Staerk J and Constantinescu SN. The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. *JAKSTAT* 2012; 1: 184–190.

10. Edahiro Y, Morishita S, Takahashi K, et al. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. *Int J Hematol* 2014; 99: 625–634.

11. Yang JJ, Chen H, Zheng XQ, et al. Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm. *Asian Pac J Cancer Prev* 2015; 16: 2219–2225.

12. Perez C, Pascual M, Martin-Subero JI, et al. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. *Haematologica* 2013; 98: 1414–1420.

13. Nischal S, Bhattacharyya S, Christopeit M, et al. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. *Cancer Res* 2013; 73: 1076–1085.

14. Mongan NP and Gudas LJ. Diverse actions of retinoid receptors in cancer prevention and treatment. *Differentiation* 2007; 75: 853–870.

15. Xiang L, Wang R, Wei J, et al. Retinoic acid receptor-beta gene reexpression and biological activity in SHI-1 cells after combined treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid. *Acta Haematol* 2015; 133: 279–286.

16. Vivaldi A, Miasaki FY, Ciampi R, et al. Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid. *Mol Cell Endocrinol* 2009; 307: 142–148.

17. Xiang L, Dong W, Wang R, et al. All-trans retinoic acid enhances the effect of 5-aza-2'-deoxycytidine on p16INK4a demethylation, and the two drugs synergistically activate retinoic acid receptor beta gene expression in the human erythroleukemia K562 cell line. *Oncol Lett* 2014; 8: 117–122.

18. Xiang L, Zhou J, Gu W, et al. Changes in expression of WT1 during induced differentiation of the acute myeloid leukemia cell lines by treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid. *Oncol Lett* 2016; 11: 1521–1526.

19. Wu W, Lin Y, Xiang L, et al. Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy. *Ann Hematol* 2016; 95: 1051–1057.

20. Saunthararajah Y, Sekeres M, Advani A, et al. Evaluation of nontoxic DNMT1-depleting therapy in patients with
myelodysplastic syndromes. *J Clin Invest* 2015; 125: 1043–1055.

21. Wang J, Yi Z, Wang S, et al. The effect of decitabine on megakaryocyte maturation and platelet release. *Thromb Haemost* 2011; 106: 337–343.

22. Chen GQ, Shen ZX, Wu F, et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. *Leukemia* 1996; 10: 825–828.